SCHEMBL31225580

SCHEMBL31225580

C#CCNc1c(NCCCCCCO[C@]2(C(=O)OC)C[C@H](OC(C)=O)[C@@H](NS(=O)(=O)c3ccccc3[N+](=O)[O-])[C@H]([C@H](OC(C)=O)[C@@H](CN=[N+]=[N-])OC(C)=O)O2)c(=O)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31225711 0.89 — —
SCHEMBL31225250 0.87 NPY5R (0.32) —
Trifluoroacetic Acid SCHEMBL31225352 0.85 TBXA2R (0.33) —
SCHEMBL31225992 0.81 CD22 (0.37) —
SCHEMBL31226042 0.77 SMN1; SMN2 (0.33) —
SCHEMBL31225435 0.77 SMN1; SMN2 (0.33) —
SCHEMBL31225119 0.77 — —
SCHEMBL31225798 0.74 CD22 (0.38) —
SCHEMBL31225439 0.72 — —
SCHEMBL31225646 0.69 NANP (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 — — US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 — — WO disclosed
Send feedback